Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 155 SEK 2.58% Market Closed
Market Cap: 12.3B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Other Current Liabilities
kr546m
CAGR 3-Years
37%
CAGR 5-Years
89%
CAGR 10-Years
52%
AddLife AB
STO:ALIF B
Other Current Liabilities
kr490m
CAGR 3-Years
14%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Other Current Liabilities
kr378.6m
CAGR 3-Years
120%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Other Current Liabilities
kr16.3m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
11%
MedCap AB (publ)
STO:MCAP
Other Current Liabilities
kr41.9m
CAGR 3-Years
41%
CAGR 5-Years
30%
CAGR 10-Years
16%
M
Magle Chemoswed Holding AB
STO:MAGLE
Other Current Liabilities
kr13.5m
CAGR 3-Years
12%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.4B SEK
Industry
Life Sciences Tools & Services

Biotage AB engages in the provision of separation and synthesis technology solutions. The company is headquartered in Uppsala, Uppsala and currently employs 497 full-time employees. The company went IPO on 2000-06-30. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The firm offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.

BIOT Intrinsic Value
196.81 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Biotage AB's Other Current Liabilities?
Other Current Liabilities
546m SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Other Current Liabilities amounts to 546m SEK.

What is Biotage AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
52%

Over the last year, the Other Current Liabilities growth was 4%. The average annual Other Current Liabilities growth rates for Biotage AB have been 37% over the past three years , 89% over the past five years , and 52% over the past ten years .

Back to Top